While B-cell aplasia has been widely used to monitor the persistence of CD19-CAR-T cells, there is no such way to define “functional persistence” in AML, which necessitates the optimization of detection approaches for monitoring CAR-T cells in the blood. This evidence concerns the gene CD19 and acute myeloid leukemia.